Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITEL-C: Vasopressin vs Terlipressin in Cirrhotics with Septic Shock
NCT05315557Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Apr 2022
- Primary completion
- Mar 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of terlipressin in septic shock (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Improvement in systemic hemodynamics at 6 hours. Status: unknown.
02
Drugs
terlipressin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT05315557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05315557.